New combo attack on liver tumors shows promise for Tough-to-Treat cancer
NCT ID NCT06071052
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a three-part treatment for people with colorectal cancer that spread to the liver and stopped responding to standard treatments. The approach combines two minimally invasive procedures (TACE and HAIC) with the targeted drug regorafenib. The goal was to see if this combination could shrink tumors and improve survival in 21 patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regorafenib
What this could lead to
If this works, it could offer a new treatment option for people with colorectal cancer that has spread to the liver and hasn't responded to standard therapies.
What could go wrong
This is a small, early-phase study with only 21 participants, so results may not apply to everyone. The combination also carries risks like liver damage or side effects from the drugs and procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the first affiliated hospital, Sun-Yat sen university
Guangzhou, Guangdong, 510000, China